Over the past 15 years glycolipid-type biosurfactant compounds have been postulated as novel, naturally synthesized anticancer agents. This study utilized a recombinant strain of Pseudo- monas aeruginosa to biosynthesize a preparation of mono-rhamnolipids that were purified via both liquid and solid-phase extraction; characterized by HPLC-MS; and utilized to treat two colorectal cancer cell lines (HCT-116 and Caco2), and a healthy colonic epithelial cell line CCD-841-CoN. Ad- ditionally, the anticancer activity of these mono-rhamnolipids was compared to an alternative nat- urally derived anticancer agent, Piceatannol. XTT cell viability assays showed that treatment with mono-rhamnolipid significantly reduced the viability of both colorectal cancer cell lines whilst hav- ing little effect on the healthy colonic epithelial cell line. At the concentrations tested mono-rham- nolipids were also shown to be more cytotoxic to the colorectal cancer cells than Piceatannol. Stain- ing of mono-rhamnolipid treated cells with propidium iodine and acridine orange appeared to show that these compounds induced necrosis in both colorectal cancer cell lines. These data provide an early in vitro proof-of-principle for utilizing these compounds either as active pharmaceutical ingredient for the treatment of colorectal cancer or incorporations into nutraceutical formulations to potentially prevent gastrointestinal tract cancer.
Bibliographical noteFunding Information:
This research was externally funded by Invest Northern Ireland, proof-of-concept grant number 826 and internally by an Ulster University Vice Chancellors Research Scholarship.
© 2022 by the authors.
- Colorectal Cancer
- Pseudomonas aeruginosa
- colorectal cancer